98%
921
2 minutes
20
Age-related cerebrovascular defects contribute to vascular cognitive impairment and dementia (VCID) as well as other forms of dementia. There has been great interest in developing biomarkers and other tools for studying cerebrovascular disease using more easily accessible tissues outside the brain such as the retina. Decreased circulating insulin-like growth factor 1 (IGF-1) levels in aging are thought to contribute to the development of cerebrovascular impairment, a hypothesis that has been supported by the use of IGF-1 deficient animal models. Here we evaluate vascular and other retinal phenotypes in animals with circulating IGF-1 deficiency and ask whether the retina mimics common age-related vascular changes in the brain such as the development of microhemorrhages. Using a hypertension-induced model, we confirm that IGF-1 deficient mice exhibited worsened microhemorrhages than controls. The retinas of IGF-1 deficient animals do not exhibit microhemorrhages but do exhibit signs of vascular damage and retinal stress such as patterns of vascular constriction and Müller cell activation. These signs of retinal stress are not accompanied by retinal degeneration or impaired neuronal function. These data suggest that the role of IGF-1 in the retina is complex, and while IGF-1 deficiency leads to vascular defects in both the brain and the retina, not all brain pathologies are evident in the retina.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959924 | PMC |
http://dx.doi.org/10.3389/fnagi.2022.788296 | DOI Listing |
Arthritis Rheumatol
July 2025
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
Objective: Interleukin-17-producing CD4 Th17 cells contribute to the pathogenesis of autoimmune diseases, including crescentic glomerulonephritis. Although ADAM9 has been reported to contribute to organ inflammation, the mechanism remains poorly understood. The goal of the current study was to investigate how ADAM9 alters T cell metabolism to promote the generation of Th17 cell differentiation.
View Article and Find Full Text PDFJ Clin Endocrinol Metab
September 2025
Developmental Endocrinology Research Group, University of Glasgow, Royal Hospital for Children, Glasgow, UK.
Objective: To understand the frequency and trends in reported outcomes of safety and effectiveness for recombinant human growth hormone (rhGH) therapy for growth hormone deficiency (GHD) in childhood.
Methods: A systematic review was performed in seven English and Chinese language databases. Eligibility criteria included all studies published between 2003 and 2022, with participants who started rhGH before the age of 16 years for GHD.
Medicine (Baltimore)
August 2025
Department of Endocrinology, Jiangxi Provincial Children's Hospital, Jiangxi, China.
This study evaluated the effects of recombinant human growth hormone (rhGH) on bone mineral density (BMD) and body composition in Chinese adolescents with transitional growth hormone deficiency (TGHD). A prospective cohort study was conducted from September 2021 to September 2024, involving 37 TGHD patients (15-18 years) and 7 healthy controls. After a 3-month rhGH washout, 9 confirmed TGHD patients (diagnosed per 2019 AACE criteria) were stratified into treatment (n = 4, rhGH continuation) and non-treatment (n = 5) groups.
View Article and Find Full Text PDFBrain Inj
August 2025
Department of Internal Medicine, Virginia Tech Carilion School of Medicine, Roanoke, VA, USA.
Objective: This study assessed the relationship between insulin-like growth factor 1 (IGF-1) level and symptom severity in adolescents with traumatic brain injury (TBI), focusing on correlation with post-injury symptom severity, depression, and anxiety.
Design: This retrospective observational study included adolescents aged 13-17 years ( = 52) with mild TBI (mTBI, = 30) or moderate/severe TBI (msTBI, = 22), based on best Glasgow Coma Scale score recorded in the first 24 h post-injury. Participants were 3-12 months post-TBI with available IGF-1 values and complete Rivermead Post Concussion Symptoms Questionnaire (RPQ-13), Generalized Anxiety Disorder-7 (GAD-7), and Patient Health Questionnaire-9 (PHQ-9) responses.
Cureus
July 2025
Academic Department of Endocrinology, Diabetes and Infectiology, Klinikum Bielefeld, Medical School and University Medical Centre East Westphalia-Lippe Bielefeld University, Bielefeld, DEU.
The simultaneous occurrence of Addison's disease and acromegaly presents a unique and complex clinical challenge. Addison's disease, characterized by autoimmune adrenal destruction, results in cortisol and aldosterone deficiencies, while acromegaly stems from excessive growth hormone secretion, usually due to a pituitary adenoma. Their coexistence complicates diagnosis and management due to overlapping systemic effects.
View Article and Find Full Text PDF